表紙
市場調查報告書
商品編碼
1019914

婦產科醫療的全球市場 (各藥物、各用途、各終端用戶、各地區):趨勢分析,各企業市場佔有率,未來預測 (2017∼2027年)

Global Women's Healthcare Market- By Drugs, By Application, By End-User, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2017-2027

出版日期: | 出版商: Blueweave Consulting & Research Private Limited | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球婦產科醫療的市場規模,2020年達到331億8202萬美元,預計2027年達461億6353萬美元。還有在預測期間內 (2021年∼2027年)預計以4.9%的年複合成長率成長。市場主要促進因素,是女性的骨質疏鬆症患者增加,及多囊性卵巢症候群 (PCOS)的盛行率上升等。在各地區中,北美各國為最大市場。

本報告提供全球婦產科醫療市場相關分析,市場基本結構和促進、阻礙因素,市場整體及各終端用戶、各原料、各類型、各地區的趨勢預測,競爭情形和資本交易趨勢,主要企業的簡介等相關調查。

目錄

第1章 分析的組成架構

第2章 分析方法

第3章 摘要整理

第4章 全球婦產科醫療市場:產業分析

  • 產業的價值鏈分析
  • DROC分析 (促進因素、阻礙因素、機會、威脅)
  • 最近的開發
  • 法規結構
  • 波特的五力分析

第5章 全球婦產科醫療市場:概要

  • 市場規模與其預測 (2017年∼2027年)
    • 以金額為準
  • 市場佔有率與其預測
    • 各藥物
      • EVISTA
      • XGEVA
      • Prolia
      • Zometa
      • Reclast/Aclasta
      • Minastrin 24 Fe
      • FORTEO
      • Premarin
      • ACTONEL
    • 各用途
      • 荷爾蒙性不孕症
      • 停經後骨質疏鬆症
      • 子宮內膜異位症
      • 避孕
      • 閉經
      • 多囊性卵巢症候群 (PCOS)
      • 其他
    • 各終端用戶
      • 醫院、診所
      • 婦產科中心
      • 分析機關
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美的婦產科醫療市場

  • 市場規模與其預測 (以金額為準,2017年∼2027年)
  • 市場佔有率與其預測
    • 各藥物
    • 各用途
    • 各終端用戶
    • 各國
      • 美國
      • 加拿大

第7章 歐洲的婦產科醫療市場

  • 市場規模與其預測 (以金額為準,2017年∼2027年)
  • 市場佔有率與其預測
    • 各藥物
    • 各用途
    • 各終端用戶
    • 各國
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他的歐洲各國

第8章 亞太地區的婦產科醫療市場

  • 市場規模與其預測 (以金額為準,2017年∼2027年)
  • 市場佔有率與其預測
    • 各藥物
    • 各用途
    • 各終端用戶
    • 各國
      • 印度
      • 中國
      • 日本
      • 韓國
      • 其他的亞太地區各國

第9章 南美的婦產科醫療市場

  • 市場規模與其預測 (以金額為準,2017年∼2027年)
  • 市場佔有率與其預測
    • 各藥物
    • 各用途
    • 各終端用戶
    • 各國
      • 阿根廷
      • 巴西
      • 墨西哥
      • 其他的南美各國

第10章 中東、非洲的婦產科醫療市場

  • 市場規模與其預測 (以金額為準,2017年∼2027年)
  • 市場佔有率與其預測
    • 各藥物
    • 各用途
    • 各終端用戶
    • 各國
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國 (UAE)
      • 南非
      • 其他的中東、非洲各國

第11章 競爭情形

  • 主要製造商與其主要產品一覽
  • 市場佔有率分析 (2020年)
  • 企業間比較分析:各經營指標

第12章 COVID-19對全球婦產科醫療市場的影響

第13章 企業簡介(企業概要,財務矩陣,主要產品環境,企業員工,主要的競爭企業,聯繫資訊,企業策略預測)

  • Bayer AG
  • Allergan
  • Becton & Dickson
  • Elly Lilly
  • Merck & Co.
  • Pfizer Inc.
  • Amgen
  • Agile Therapeutics Inc.
  • Ferring Pharmaceuticals
  • Mylan N.V.
  • Lupin
  • Blairex Laboratories
  • Apothecium Pharmaceutical
  • Other Prominent Players

第14章 主要策略建議

目錄
Product Code: BWC20103

Global Women's Healthcare Market Set to Register Moderate Growth: Expected to Reach USD 46,163.53 million in 2027

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global women's healthcare market reached USD 33,182.02 million in 2020. The data estimated by the study further reveals that the market is projected to reach USD 46,163.53 million by 2027, growing at a CAGR of 4.9% during 2021-2027 (forecast period). The global women's healthcare market is expanding due to rising government measures to reduce population, an increase in the frequency of chronic illnesses among women worldwide, and a surge in demand for contraception to minimize unintended pregnancies. This has raised the demand for women's healthcare, favorably impacting the worldwide women's healthcare market.

The rise in women-specific health disorders is amplifying the global women's healthcare market

According to a report published by the International Osteoporosis Foundation (IOF), the global incidence of osteoporosis among females is expected to reach 680 million by 2050. According to the Society of Obstetricians and Gynecologists of Canada (SOGC), around 80% of women experience more than one menopausal symptom, such as disrupted sleep, mood fluctuations, and increased irritability. Also, the GLOBOCAN report for the year 2018 released by the International Agency for Research on Cancer (IARC) states that female breast cancer diagnosis totaled 2.1 million cases in 2018, accounting for an estimated 11.6% of all global cancer cases. As a result, the rapid rise in the number of women-specific health disorders is generating demand for the global women's healthcare market.

Growing Prevalence of Polycystic Ovary Syndrome (PCOS) have contributed to the growth of the global women's healthcare market

PCOS is a hormonal disorder prevalent in premenopausal women worldwide, causing reproductive, endocrine, and metabolic abnormalities. The surge in the number of cases of PCOS has significantly assisted in the growth of the global women's healthcare market since it requires a strict medical regimen. Oral contraceptive combinations, particularly those containing progestins such as norgestimate, desogestrel, or drospirenone (due to their minimal androgenic effects), are among the most often used drugs for hirsutism in women with PCOS. Hormonal aberrations are common in women with PCOS (elevated androgen levels) leading to menstrual irregularities like oligomenorrhea, amenorrhea, and others, which causes dysfunctional uterine bleeding & infertility. Thus, the wide range of medications used for treating PCOS and the rise in instances of PCOS are contributing to the global women's healthcare market's growth.

The Prolia drug sub-segment occupies the largest market share in the global women's healthcare market

Based on drugs, the global women's healthcare market is segmented into EVISTA, XGEVA, Prolia, Zometa, Reclast/Aclasta, Minastrin 24 Fe, FORTEO, Premarin, ACTONEL, and others. Prolia accounted for the largest market share in the global women's healthcare market in 2020 and is further projected to record a strong CAGR during the forecast period (2021-2027). The drug acts as an effective medicine for curing osteoporosis in women. Since women are more prone to confront bone and calcium-related issues than men, the need for bone-related treatment becomes inevitable making the drug more essential for consumption. As a result, the drug has been driving the growth of the global women's healthcare market.

The hospitals & clinics segment registered the largest share in the global women's healthcare market's end-user segment

Based on end-users, the global women's healthcare market is segmented into hospitals & clinics, gynecology centers, research institutes, and others. The hospitals & clinics segment accounted for the largest share in the global women's healthcare market and is expected to register a healthy CAGR during the forecast period. People prefer visiting hospitals and gynaecology centers owing to the presence of specialized and highly qualified surgeons and physicians. The growing insurance and reimbursement policies driven by the government initiatives in various developed regions have been driving women to opt for treatments in hospitals.

The Global Women's Healthcare Market: Regional Insights

Based on region, the global women's healthcare market is divided into North America, Europe, the Asia-Pacific, Latin America, and the Middle East and Africa. In the year 2020, the North American region accounted for the greatest market share in the global women's healthcare market. According to U.S. census demographics, the region has a growing female population over the age of 35, which indicates a rising demand for female healthcare. This will have a significant impact on the demand for treatment and drugs associated with women's healthcare in the region, as well as the global women's healthcare market.

COVID-19 Impact Analysis

The UN report on the impact of COVID-19 on women discovered that overburdened health facilities, as a result of COVID-19, are diverting resources away from services women require, such as pre- and post-natal healthcare and contraception. When it comes to accessing help, women confront unique challenges. According to the findings of a recent UN Women and UNFPA report, 'Impact of COVID-19 on Gender Equality and Women's Empowerment in East and Southern Africa', the pandemic has had far-reaching and diversified repercussions on women and girls in East and Southern Africa. Additionally, there has been an upsurge in the incidence of neonatal and maternal problems in COVID-19 positive pregnant mothers. It has resulted in an increased rate of miscarriage, preterm birth, pre-eclampsia, cesarean section, and perinatal death. These fatal complications have created the demand for an effective and accessible women's healthcare market for all of its users worldwide.

Some of the leading players in the global women's healthcare market are Bayer AG, Allergan, Becton & Dickson, Elly Lilly, Merck & Co, Pfizer Inc., Amgen, Agile Therapeutics Inc., Ferring Pharmaceuticals Mylan N.V., and other prominent players. The prevalence of various women's healthcare manufacturers around the world has paved the way for rising opportunities among the new entrants in the global women's healthcare market owing to which the global women's healthcare is fragmented in nature.

In May 2021, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE, the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.

Don't miss the business opportunity of the Global Women's Healthcare market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of global women's healthcare market size & forecast. The report promises to provide recent technology trends of the global women's healthcare market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the global women's healthcare market.

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer all-inclusive market research reports by analysing both qualitative and quantitative data to boost up the performance of your business solutions. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Systematic Research Approach
  • 2.2. Quantitative Research & Quantitative Research
  • 2.3. Breakdown of Primary Research Respondents
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Market Breakdown & Data Triangulation
  • 2.5. Assumptions & Limitations

3. Executive Summary

4. Global Women's Healthcare Market - Industry Insights

  • 4.1. Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunity
    • 4.2.4. Challenges
  • 4.3. Recent Developments
  • 4.4. Regulatory Framework
  • 4.5. Porter five Forces Analysis

5. Global Women's Healthcare Market Overview

  • 5.1. Market Size & Forecast by Value, 2017-2027
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs
      • 5.2.1.1. EVISTA
      • 5.2.1.2. XGEVA
      • 5.2.1.3. Prolia
      • 5.2.1.4. Zometa
      • 5.2.1.5. Reclast/Aclasta
      • 5.2.1.6. Minastrin 24 Fe
      • 5.2.1.7. FORTEO
      • 5.2.1.8. Premarin
      • 5.2.1.9. ACTONEL
    • 5.2.2. By Application
      • 5.2.2.1. Hormonal Infertility
      • 5.2.2.2. Postmenopausal Osteoporosis
      • 5.2.2.3. Endometriosis
      • 5.2.2.4. Contraceptives
      • 5.2.2.5. Menopause
      • 5.2.2.6. Polycystic Ovary Syndrome
      • 5.2.2.7. Other
    • 5.2.3. By End-Users
      • 5.2.3.1. Hospitals & Clinics
      • 5.2.3.2. Gynecology Centers
      • 5.2.3.3. Research Institutes
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. The Asia-Pacific
      • 5.2.4.4. Latin America
      • 5.2.4.5. The Middle East & Africa

6. North America Women's Healthcare Market

  • 6.1. Market Size & Forecast by Value, 2017-2027
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Application
    • 6.2.3. By End-Users
    • 6.2.4. By Country
      • 6.2.4.1. United States
      • 6.2.4.2. Canada

7. Europe Women's Healthcare Market

  • 7.1. Market Size & Forecast by Value, 2017-2027
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Application
    • 7.2.3. By End-Users
    • 7.2.4. By Country
      • 7.2.4.1. Germany
      • 7.2.4.2. United Kingdom
      • 7.2.4.3. France
      • 7.2.4.4. Italy
      • 7.2.4.5. Spain
      • 7.2.4.6. Rest of Europe

8. Asia Pacific Women's Healthcare Market

  • 8.1. Market Size & Forecast by Value, 2017-2027
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Application
    • 8.2.3. By End-Users
    • 8.2.4. By Country
      • 8.2.4.1. India
      • 8.2.4.2. China
      • 8.2.4.3. Japan
      • 8.2.4.4. South Korea
      • 8.2.4.5. Rest of Asia Pacific

9. Latin America Women's Healthcare Market

  • 9.1. Market Size & Forecast by Value, 2017-2027
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Application
    • 9.2.3. By End-Users
    • 9.2.4. By Country
      • 9.2.4.1. Argentina
      • 9.2.4.2. Brazil
      • 9.2.4.3. Mexico
      • 9.2.4.4. Rest of Latin America

10. Middle East & Africa Women's Healthcare Market

  • 10.1. Market Size & Forecast by Value, 2017-2027
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By Application
    • 10.2.3. By End-Users
    • 10.2.4. By Country
      • 10.2.4.1. Saudi Arabia
      • 10.2.4.2. UAE
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1. List of Key Producers and Their Offerings
  • 11.2. Market Share Analysis (2020)
  • 11.3. Competitive Benchmarking, By Operating Parameters

12. Impact of COVID-19 on Global Women's Healthcare Market

13. Company Profiles (Company Overview, Financial Matrix, Key Application landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 13.1. Bayer AG
  • 13.2. Allergan
  • 13.3. Becton & Dickson
  • 13.4. Elly Lilly
  • 13.5. Merck & Co.
  • 13.6. Pfizer Inc.
  • 13.7. Amgen
  • 13.8. Agile Therapeutics Inc.
  • 13.9. Ferring Pharmaceuticals
  • 13.10. Mylan N.V.
  • 13.11. Lupin
  • 13.12. Blairex Laboratories
  • 13.13. Apothecium Pharmaceutical
  • 13.14. Other Prominent Players

14. Key Strategic Recommendations

*Financial details of unlisted companies will be available as per data availability in final deliverable

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable